Cite
Kanda T, Nakamura M, Yasui S, et al. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017;6(2)doi: 10.3390/biology6020030.
Kanda, T., Nakamura, M., Yasui, S., Haga, Y., Tawada, A., Suzuki, E., Ooka, Y., Takahashi, K., Sasaki, R., Wu, S., Nakamoto, S., Arai, M., Imazeki, F., & Yokosuka, O. (2017). Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology, 6(2), . https://doi.org/10.3390/biology6020030
Kanda, Tatsuo, et al. "Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin." Biology vol. 6,2 (2017). doi: https://doi.org/10.3390/biology6020030
Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017 May 09;6(2). doi: 10.3390/biology6020030. PMID: 28486403; PMCID: PMC5485477.
Copy
Download .nbib